Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 5
2020 4
2021 2
2022 7
2023 13
2024 14
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Reply by Authors.
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Fossati N, et al. Among authors: robesti d. J Urol. 2020 Aug;204(2):302. doi: 10.1097/JU.0000000000000800.03. Epub 2020 May 19. J Urol. 2020. PMID: 32427046 No abstract available.
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.
Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol Oncol. 2023 Dec;6(6):543-552. doi: 10.1016/j.euo.2023.05.003. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37270378
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, Stabile A, Beauval JB, Malavaud B, Roumiguié M, Robesti D, Dell'Oglio P, Moschini M, Zamboni S, Rakauskas A, De Cobelli F, Porpiglia F, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2019 Mar;75(3):506-514. doi: 10.1016/j.eururo.2018.10.012. Epub 2018 Oct 17. Eur Urol. 2019. PMID: 30342844 Free article.
What to expect from the novel pulsed thulium:YAG laser? A systematic review of endourological applications.
Ventimiglia E, Robesti D, Bevilacqua L, Tondelli E, Oliva I, Orecchia L, Juliebø-Jones P, Pietropaolo A, De Coninck V, Esperto F, Tailly T, Ferretti S, Gauhar V, Somani B, Villa L, Keller EX, Salonia A, Traxer O, Kartalas Goumas I. Ventimiglia E, et al. Among authors: robesti d. World J Urol. 2023 Nov;41(11):3301-3308. doi: 10.1007/s00345-023-04580-z. Epub 2023 Sep 8. World J Urol. 2023. PMID: 37682286
Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, Cisero E, Semko S, Checcucci E, Devos G, Apfelbeck M, Gatti C, Marra G, van den Bergh RCN, Goldner G, Rasul S, Ceci F, Dal Moro F, Porpiglia F, Gontero P, Bjartell A, Stief C, Heidenreich A, Joniau S, Briganti A, Shariat SF, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Rajwa P, et al. Among authors: robesti d. Eur Urol Oncol. 2024 Aug;7(4):721-734. doi: 10.1016/j.euo.2023.09.006. Epub 2023 Oct 14. Eur Urol Oncol. 2024. PMID: 37845121 Free article.
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Fallara G, Robesti D, Nocera L, Raggi D, Marandino L, Belladelli F, Montorsi F, Malavaud B, Ploussard G, Necchi A, Martini A. Fallara G, et al. Among authors: robesti d. Cancer Treat Rev. 2022 Nov;110:102441. doi: 10.1016/j.ctrv.2022.102441. Epub 2022 Jul 26. Cancer Treat Rev. 2022. PMID: 35939976 Review.
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study.
Quarta L, Mazzone E, Cannoletta D, Stabile A, Scuderi S, Barletta F, Cucchiara V, Nocera L, Pellegrino A, Robesti D, Leni R, Zaurito P, Brembilla G, De Cobelli F, Samanes Gajate AM, Picchio M, Chiti A, Montorsi F, Briganti A, Gandaglia G. Quarta L, et al. Among authors: robesti d. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3789-3798. doi: 10.1007/s00259-024-06789-5. Epub 2024 Jun 11. Eur J Nucl Med Mol Imaging. 2024. PMID: 38861182 Free PMC article. Clinical Trial.
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P, Pissavini A, Presutti M, Farolfi A, Mei R, Castellucci P, Gandaglia G, Larcher A, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: robesti d. Cancers (Basel). 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027. Cancers (Basel). 2023. PMID: 37046687 Free PMC article.
"Urological age" as a proxy of healthy longevity: analysis of prospective population-based cohorts in U.S. and China.
Jin Y, Huang W, Zeng B, Yang L, Wang S, Manuel C, Daniele R, Deng L, Leng S, Hu D, Wang D, Jiang Z, Yi Q, Zhang L, Zeng Y, Zhu W, Sheng L, Liu X, Wei Q, Qiu S. Jin Y, et al. Among authors: daniele r. Int J Surg. 2024 Jul 25;111(1):502-11. doi: 10.1097/JS9.0000000000001965. Online ahead of print. Int J Surg. 2024. PMID: 39051917 Free PMC article.
Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer.
Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Mossa F, et al. Among authors: robesti d. Mol Cancer Res. 2023 Jan 3;21(1):51-61. doi: 10.1158/1541-7786.MCR-22-0250. Mol Cancer Res. 2023. PMID: 36112348 Free PMC article.
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2022 Oct;82(4):411-418. doi: 10.1016/j.eururo.2022.06.002. Epub 2022 Jul 22. Eur Urol. 2022. PMID: 35879127 Free article. Clinical Trial.
Ho:YAG laser and temperature: is it safe to use high-power settings?
Robesti D, Villa L, Saccomandi P, Traxer O, Salonia A, Ventimiglia E. Robesti D, et al. World J Urol. 2022 Jul;40(7):1891-1892. doi: 10.1007/s00345-022-04014-2. Epub 2022 Apr 19. World J Urol. 2022. PMID: 35438313 No abstract available.
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.
Fallara G, Belladelli F, Robesti D, Raggi D, Nocera L, Marandino L, Galsky MD, Montorsi F, Malavaud B, Ploussard G, Necchi A, Martini A. Fallara G, et al. Among authors: robesti d. Crit Rev Oncol Hematol. 2022 Nov;179:103801. doi: 10.1016/j.critrevonc.2022.103801. Epub 2022 Aug 27. Crit Rev Oncol Hematol. 2022. PMID: 36031173 Review.
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.
Nocera L, Fallara G, Raggi D, Belladelli F, Robesti D, Montorsi F, Karakiewicz PI, Malavaud B, Ploussard G, Necchi A, Martini A. Nocera L, et al. Among authors: robesti d. Front Oncol. 2022 Sep 5;12:955894. doi: 10.3389/fonc.2022.955894. eCollection 2022. Front Oncol. 2022. PMID: 36132135 Free PMC article.
Temperature profile during endourological laser activation: introducing the thermal safety distance concept.
Ventimiglia E, Robesti D, Keller EX, Corsini C, Folcia A, Fantin M, Candela L, Pozzi E, Sierra A, Pietropaolo A, Somani BK, Panthier F, Pauchard F, Goumas IK, Villa L, Montorsi F, Traxer O, Salonia A, Saccomandi P. Ventimiglia E, et al. Among authors: robesti d. World J Urol. 2024 Jul 29;42(1):453. doi: 10.1007/s00345-024-05162-3. World J Urol. 2024. PMID: 39073430
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Pellegrino F, Stabile A, Sorce G, Mazzone E, Cannoletta D, Cirulli GO, Quarta L, Leni R, Robesti D, Brembilla G, Gandaglia G, De Cobelli F, Montorsi F, Briganti A. Pellegrino F, et al. Among authors: robesti d. Prostate. 2024 Apr;84(5):473-478. doi: 10.1002/pros.24665. Epub 2023 Dec 27. Prostate. 2024. PMID: 38149793
Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology.
Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F, Sierra A, Juliebø-Jones P, Kwok JL, Tsaturyan A, Contreras P, Fossati N, Gallina A, Xavier Keller E, Knoll T, Kartalas Goumas I, Somani BK, Traxer O, Salonia A, Ventimiglia E. Corsini C, et al. Among authors: robesti d. Eur Urol Focus. 2024 Nov 13:S2405-4569(24)00215-3. doi: 10.1016/j.euf.2024.10.009. Online ahead of print. Eur Urol Focus. 2024. PMID: 39542788 Review.
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.
Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, Pissavini A, Mei R, Farolfi A, Castellucci P, Puliatti S, Larcher A, Gandaglia G, Robesti D, Mottrie A, Briganti A, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Bianchi L, et al. Among authors: robesti d. Cancers (Basel). 2022 Dec 30;15(1):247. doi: 10.3390/cancers15010247. Cancers (Basel). 2022. PMID: 36612242 Free PMC article.
Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer.
Martini A, Gandaglia G, Fossati N, Scuderi S, Bravi CA, Mazzone E, Stabile A, Scarcella S, Robesti D, Barletta F, Cucchiara V, Mirone V, Montorsi F, Briganti A. Martini A, et al. Among authors: robesti d. Eur Urol Oncol. 2021 Feb;4(1):42-48. doi: 10.1016/j.euo.2019.03.006. Epub 2019 Apr 5. Eur Urol Oncol. 2021. PMID: 31411971
Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022;82:501-509.
Montorsi F, Gandaglia G, Robesti D, Dehò F, Briganti A. Montorsi F, et al. Among authors: robesti d. Eur Urol. 2022 Nov;82(5):e143. doi: 10.1016/j.eururo.2022.07.035. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35989206 Clinical Trial. No abstract available.
Understanding the Role of Ureteral Access Sheath in Preventing Post-Operative Infectious Complications in Stone Patients Treated with Ureteroscopy and Ho:YAG Laser Lithotripsy: Results from a Tertiary Care Referral Center.
Villa L, Dioni P, Candela L, Ventimiglia E, De Angelis M, Corsini C, Robesti D, Fantin M, D'Arma A, Proietti S, Giusti G, Kartalas Goumas I, Briganti A, Montorsi F, Salonia A. Villa L, et al. Among authors: robesti d. J Clin Med. 2023 Feb 12;12(4):1457. doi: 10.3390/jcm12041457. J Clin Med. 2023. PMID: 36835992 Free PMC article.
Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A, Gandaglia G, de Angelis M, Fallara G, Mazzone E, Stabile A, Pellegrino F, Robesti D, Leni R, Scuderi S, Cucchiara V, Cirulli GO, Barletta F, Montorsi F, Briganti A. Pellegrino A, et al. Among authors: robesti d. World J Urol. 2023 Aug;41(8):2069-2076. doi: 10.1007/s00345-023-04460-6. Epub 2023 Jun 16. World J Urol. 2023. PMID: 37326656
Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series.
Leni R, Gandaglia G, Stabile A, Mazzone E, Pellegrino F, Scuderi S, Robesti D, Barletta F, Cirulli GO, Cucchiara V, Zaffuto E, Dehò F, Montorsi F, Briganti A. Leni R, et al. Among authors: robesti d. Eur Urol Oncol. 2023 Oct;6(5):493-500. doi: 10.1016/j.euo.2023.02.014. Epub 2023 Mar 31. Eur Urol Oncol. 2023. PMID: 37005213
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Mazzone E, et al. Among authors: robesti d. Eur Urol Oncol. 2024 Apr;7(2):231-240. doi: 10.1016/j.euo.2023.08.010. Epub 2023 Sep 9. Eur Urol Oncol. 2024. PMID: 37689506
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.
Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Böhmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Martini A, et al. Among authors: robesti d. Eur Urol Oncol. 2021 Apr;4(2):301-304. doi: 10.1016/j.euo.2019.11.003. Epub 2019 Dec 4. Eur Urol Oncol. 2021. PMID: 31810893 Clinical Trial.
Perioperative outcomes, environmental impact and economic implications of pelvic drain discontinuation in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Scuderi S, Scilipoti P, Nocera L, Longoni M, Quarta L, Zaurito P, Barletta F, Pellegrino F, de Angelis M, Robesti D, Pellegrino A, Stabile A, Larcher A, Montorsi F, Briganti A, Gandaglia G. Scuderi S, et al. Among authors: robesti d. Urol Oncol. 2024 Dec 16:S1078-1439(24)00776-2. doi: 10.1016/j.urolonc.2024.11.022. Online ahead of print. Urol Oncol. 2024. PMID: 39690076
The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.
Robesti D, Moschini M, Pio Tenace N, Burgio G, Re C, Leni R, De Angelis M, Scilipoti P, Pellegrino F, Cannoletta D, Gandaglia G, Fossati N, Gallina A, Doglioni C, Colecchia M, Salonia A, Montorsi F, Briganti A, Lucianò R. Robesti D, et al. Eur Urol Focus. 2024 Jun 26:S2405-4569(24)00096-8. doi: 10.1016/j.euf.2024.06.007. Online ahead of print. Eur Urol Focus. 2024. PMID: 38937195
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, Cirulli G, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, Briganti A, Gandaglia G. Pellegrino F, et al. Among authors: robesti d. Eur Urol Focus. 2024 Jul;10(4):634-640. doi: 10.1016/j.euf.2023.10.006. Epub 2023 Oct 19. Eur Urol Focus. 2024. PMID: 37865591
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Bravi CA, et al. Among authors: robesti d. Eur Urol. 2020 Dec;78(6):779-782. doi: 10.1016/j.eururo.2020.06.047. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624281
Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Fossati N, et al. Among authors: robesti d. J Urol. 2020 Aug;204(2):296-302. doi: 10.1097/JU.0000000000000800. Epub 2020 Feb 18. J Urol. 2020. PMID: 32068488
The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy.
Gandaglia G, Bravi CA, Dell'Oglio P, Mazzone E, Fossati N, Scuderi S, Robesti D, Barletta F, Grillo L, Maclennan S, N'Dow J, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2018 Jul;74(1):4-7. doi: 10.1016/j.eururo.2018.02.025. Epub 2018 Mar 12. Eur Urol. 2018. PMID: 29544735
Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: robesti d. Eur Urol. 2019 May;75(5):817-825. doi: 10.1016/j.eururo.2018.10.042. Epub 2018 Nov 5. Eur Urol. 2019. PMID: 30409676
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Bravi CA, et al. Among authors: robesti d. Eur Urol. 2020 Nov;78(5):661-669. doi: 10.1016/j.eururo.2020.06.043. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624288 Free PMC article.
Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.
Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Fossati N, et al. Among authors: robesti d. Eur Urol. 2019 Oct;76(4):443-449. doi: 10.1016/j.eururo.2019.02.004. Epub 2019 Feb 22. Eur Urol. 2019. PMID: 30799187
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.
Fallara G, Belladelli F, Robesti D, Malavaud B, Tholomier C, Mokkapati S, Montorsi F, Dinney CP, Msaouel P, Martini A. Fallara G, et al. Among authors: robesti d. Urol Oncol. 2025 Jan 8:S1078-1439(24)01047-0. doi: 10.1016/j.urolonc.2024.12.267. Online ahead of print. Urol Oncol. 2025. PMID: 39788823